Galera KOL Hour: Mitigating Kidney Damage in Platinum-Based Cancer Treatments

Galera KOL Hour: Mitigating Kidney Damage in Platinum-Based Cancer Treatments

Virtual, May 22, 2020

Galera_May2020_mchbfk.jpg

Please join us for a discussion on the effects of toxicity in cancer medicine and how new advances in medicine could potentially afford better quality of life and reduce lifelong burden of care for patients. Webcast available at the link below or via the events page in the investors section of Galera's website, www.galeratx.com. 

Join the webcast here

Audience Q&A will immediately follow the interview.

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Galera Therapeutics [GRTX] US$271 MM MCap
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cus­ing on trans­form­ing ra­dio­ther­a­py in can­cer. Lead as­set GC4419 is a po­tent, high­ly se­lec­tive small molecule dis­mu­tase mimet­ic be­ing de­vel­oped for se­vere oral mu­cosi­tis, cur­rent­ly in Phase 3 with Break­through Ther­a­py Desig­na­tion. To­p­line re­sults ex­pect­ed in 1H21. Top line re­sults in Phase 1b/2a in se­cond as­set, GC4419 in pan­cre­at­ic can­cer ex­pect­ed in 2H20. GC4419 ex­pect­ed to ini­ti­ate in Phase 1b/2a in lung can­cer in 2H20. [more in­for­ma­tion]